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Abstract: This study was aimed to investigate whether the a lipid extract from Acrocomia crispa fruits (D-005) inhibits COX and 5-LOX 
enzyme activities in vitro. This study demonstrates that D-005 inhibits markedly and in a dose dependent manner COX-2 and 5-LOX 
activities. The dual inhibition of COX-2 and 5-LOX supports further research on the potential anti-inflammatory effect of D-005.  
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Resumen: El objetivo de este estudio fue investigar si el extracto lipídico de los frutos de Acrocomia crispa (D-005) inhibe in vitro las 
actividades de las enzimas COX y 5-LOX. Este estudio demuestra que el D-005 inhibe marcadamente y de manera dosis dependiente las 
actividades de la COX-2 y 5-LOX. La inhibición dual de la COX-2 y 5-LOX soportan futuras investigaciones sobre el potencial efecto anti-
inflamatorio del D-005. 
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INTRODUCTION 
Benign prostatic hyperplasia (BPH) is a common 
urological disease in aging men and it is frequently 
associated with troublesome lower urinary tract 
symptoms (LUTS), such as weak urinary stream, 
frequency and urgency (Roehrborn, 2011).  
Phytotherapeutic alternatives have been used 
to manage BPH for decades, their efficacy being 
based in multiple mechanisms, such as the inhibition 
of 5-reductase activity, antagonism of α-
adrenoreceptors (α-ADR), as well as on anti-
inflammatory and antioxidant effects (Sun & Zhang, 
2014; Pagano et al., 2014; Allkanjari & Vitalone, 
2015). Lipid extracts from the fruits of saw palmetto 
palm represent the main phytotherapy for BPH 
(Pharmacopeial Convention, 2005). Despite some 
negative results (MacDonald et al., 2012), several 
clinical studies and popular use document that the 
efficacy and safety of saw palmetto (Sinescu et al., 
2011; Giulianelli et al., 2012), recent evidence 
supports that saw palmetto soft capsules it improves 
not only BPH symptoms, but erectile sexual 
dysfunction in men with both entities (Suter et al., 
2013). Experimental studies have demonstrated that 5 
α-reductase enzyme inhibition, α-ADR antagonism, 
antioxidant and anti-inflammatory effects are 
included among the different mechanisms that 
support the efficacy of saw palmetto (Belostotskaia et 
al., 2006; Minciullo et al., 2014). The palms, quite 
abundant in Cuba, represent a relevant source for 
ethnomedicine of the American continent 
(Sosnowska & Balslev, 2009).  
Moreover, D-004, a lipid extract from the 
Cuban royal palm (Roystonea regia) fruits has been 
effective on model experimental prostatic hyperplasia 
(Carbajal et al., 2004; Noa et al., 2005; Carbajal et 
al., 2005; Arruzazabala et al., 2005; Arruzazabala et 
al., 2006; Pérez et al., 2006) and in patients with 
(BPH) (Pérez et al., 2008; López et al., 2009; 
Guzmán et al., 2013a; Guzmán et al., 2013b). 
Evidence support that the efficacy of D-004 involves 
the inhibition of prostate 5α-reductase activity, and 
the antagonism of α1-ADR -mediated responses 
(Carbajal et al., 2005; Pérez et al., 2006). Antioxidant 
and anti-inflammatory effects, however, may also 
contribute to D-004 efficacy in BPH (Menéndez et 
al., 2007; Pérez et al., 2008; López et al., 2009). 
Experimental studies have proven that D-004 inhibits 
both COX and 5-LOX activities, which supports the 
anti-inflammatory action of D-004 (Menéndez et al., 
2006; Menéndez et al., 2007; Oyarzábal et al., 2014). 
The COX and 5-LOX enzymes are involves in high 
levels of arachidonic acid (AA) produced by the 
action of phospholipase A2 on membrane 
phospholipids, which is then metabolized through the 
COX and LOX pathways to produce prostaglandins 
(PG), thromboxanes, prostacyclins, and inflammatory 
leukotrienes (LT). (Menéndez et al., 2006). 
Based on the exiting research it is significant 
to search for of potential pharmacological effects, 
useful for manage BPH or other pathological entities, 
in the extracts of the fruits of other palm species. 
Acrocomia crispa (Cuban belly palm, Corojo palm), 
endemic to Cuba (Henderson et al., 1995; Govaerts 
& Dransfield, 2005), after a literature review (2000 - 
2015) evidence associated to any pharmacological 
effect was not found (Entrez PubMed, search the 
June 2000 to June 2015).  
A lipid extract from Acrocomia crispa fruits 
(D-005) obtained in our centre shows a reproducible 
mixture of fatty acids, but different from that of D-
004 and saw palmetto extracts. This extract contains 
a mixture of fatty acids, mainly oleic, palmitic, lauric, 
linoleic, and myristic acids. Previous studies had 
demonstrated that saturated and unsaturated fatty 
acids, such as myristic, steraic, palmitic, oleic and 
several oils extracts containing fatty acids inhibit 
COX and LOX, in vitro (Naidu, 1995; Chan et al., 
1996; Henry et al., 2002; Zhang et al., 2002; 
Menéndez et al., 2007)  
Previous studies demonstrated the non-
toxicity of D-005 following acute oral administration 
to mice and rabbits (Gutierrez et al., 2016a; Gutierrez 
et al., 2016b). 
Therefore, this study was aimed to 
investigate whether D-005 inhibits COX and 5-LOX 
enzyme activities in vitro.  
 
MATERIALS AND METHODS 
Animals 
Male Wistar rats (180 - 200g), from the Center for 
Laboratory Animals Production (CENPALAB, 
Habana, Cuba) were adapted for 7 days to laboratory 
conditions: controlled temperature 25 ± 2º C, relative 
humidity 60 ± 5% and 12 hours light/dark cycles. 
Food (rodent pellets from CENPALAB) and water 
were provided ad libitum. After a 12 hour fast rats 
were anaesthetized in ether atmosphere, sacrificed by 
exsanguinations.  
Animal handle was conducted according to 
the Cuban Code for the Use of Laboratory Animals 
and ethical principles for animal management Nº 
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39/04. An independent ethical board approved the 
study protocol and use of the animals for such aim 
(Cuban Guidelines for the laboratory animals care, Nº 
39/2004). 
 
Materials 
All chemicals were purchased from Sigma-Aldrich 
Co. (St Louis, MO), except 2, 2 azo-bis-2-
amidinopropane hydrochloride (ABAP), obtained 
from Polyscience (Warington, PA). Ultracentrifuge 
was from Beckman (Beckman Instruments, Inc. Palo 
Alto, CA) and Ultrospec-Plus spectrophotometer 
from LKB (Pharmacia LKB Biotechnology, Uppsala, 
Sweden). Standards of gas chromatography, Ácidos: 
octanoico (Caprílico, C8:0), decanoico (Cáprico, 
C10:0), dodecanoico (Láurico, C12:0), tridecanoico 
(C13:0), tetradecanoico (mirístico, C14:0), 
hexadecenoico (cis-9-palmitoléico, C16:1), 
hexadecanoico (palmítico, C16:0), octadecanoico 
(esteárico, C18:0) y octadecenoico (cis-9-oleico, 
C18:1),  (p.a., Sigma, EUA). 
 
Administration and dosage 
D-005 consisted of a lipid extract obtained from the 
dried mature fruits of Acrocomia crispa collected at 
the north shore of west Havana, being duly 
authenticated by the Cuban Botanic Garden (Havana, 
Cuba) voucher number 1982-1031. Plant material 
was powdered and passed through mesh of size 236 
mm and then subjected to extraction and purification 
in hexane and basic hydrolysis with KOH. D-005 was 
obtained from the Chemistry Department of the 
Centre of Natural Products (Havana, Cuba), its 
composition and purity being controlled by gas 
chromatography with standards. The fatty acids 
content of the tested batch was as follows (w/w, %): 
lauric (35.8%), oleic (28.4%), myristic (14.2%), 
palmitic (8.9%), stearic (3.3%), capric (1.9%), 
caprylic (1.2%), and palmitoleic (0.05%). Purity 
(total content of these free fatty acids) was 93% 
(Rodríguez, 2013).  
D-004, supplied by the Plants of Natural 
Products (Havana, Cuba), had the following fatty 
acids composition, which was controlled by gas 
chromatography (w/w, %): lauric (23.6%), oleic 
(41.9%), myristic (10.6%), palmitic (11.4%), stearic 
(2.9%), capric (0.6%), caprylic (0.3%), and 
palmitoleic (0.3%). Purity (total content of these fatty 
acids) was 91% (Sierra et al., 2014).  
For the experiments, D-004 and D-005 were 
suspended in 2% Tween 65/water vehicle. INDO 
(Cuban Pharmaceutical Industry -QUIMEFA-) was 
dissolved in 5% sodium bicarbonate. 
Cytosolic microsomal preparations from rat 
platelet rich plasma (PRP) and rat seminal vesicles 
were used for assessing COX-1 and COX-2 enzyme 
activities, respectively, whereas the cytosolic fraction 
of polymorphonuclear leukocytes (PMNL) was used 
for determining 5-LOX activity.  
 
Preparation of the rat platelets microsomal fraction 
The effects on COX-1 activity were assessed by 
using microsomal preparations from rat platelets. 
Briefly, venous blood samples were collected in 
tubes containing sodium citrate (3.8%) (9:1, v/v). The 
tubes were centrifuged at 160 x g for 10 min at 10º C 
and the supernatant was centrifuged again at 2100 x g 
for 10 min at 10º C. The pellet was re-suspended in 
Tris-HCl EDTA (50 mol/l, pH 7.4, 1 mol/l EDTA) 
and ammonium oxalate (2%) (1:20, v/v) and 
centrifuged at 2100 x g for 10 min at 4º C. The pellet 
was re-suspended the same Tris-HCl EDTA buffer, 
sonicated (3 cycles of 30 sec, sub-maximal potency) 
and centrifuged at 15.000 x g for 20 min at 4º C. 
Finally, the supernatant was centrifuged at 100 000 x 
g for 2 hours at 4º C. The pellet (platelets microsomal 
fraction) was re-suspended in 0.05 mol/l Tris/HCl 
buffer (pH = 8.4) containing 0.01% Triton X-100 
(1:9, w/v) and frozen at -20º C until use (Boyum, 
1983).  
 
Preparation of the rat seminal vesicles microsomal 
fraction 
The effects on COX-2 activity were assessed by 
using microsomal preparations from rat seminal 
vesicles. In brief, seminal vesicle slices were 
homogenized in 0.05 mol/l Tris/HCl buffer (pH = 
8.4) containing 0.01% Triton X-100 (1:9, p/v) with a 
potter. The homogenates were centrifuged at 15.000 
x g for 15 min and the supernatant was centrifuged 
again at 100 000 x g for 1 hour, all operations being 
carried out at 4º C, the pellet (microsomal fraction) 
was frozen at -20º C until use (Neeraja et al., 2005).  
 
Preparation of the PMNLs cytosolic fraction 
Effects on 5-LOX activity were assessed by using 
enzyme preparations from the from the cytosolic 
fraction of freshly isolated blood  was obtained  the 
PMNLs. Briefly, venous blood samples were 
collected in tubes containing EDTA (10%), and then 
diluted in 0.9% of saline solution (NaCl 0.9%) to 10 
ml. Six (6) ml of diluted blood were then gently 
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layered over 3 ml of 14.1% Nycodenz (density 1.077 
g/ml, 20º C) prepared in 0.44% NaCl and 5 mmol/l 
Tris HCl buffer (pH = 7.2), and centrifuged at 800 x 
g for 30 min. at 20º C. After centrifugation, the 
mononuclear cells formed as band at the Nycodenz-
plasma interface were removed with a Pasteur 
pipette, washed with 50 mmol/l phosphate 
buffer/1mmol/l EDTA (pH = 7.4), and centrifuged at 
400 x g for 10 min. The pellet was washed again in 
buffer, re-suspended in the same buffer and then used 
as the crude enzyme preparation. For obtaining the 
cytosolic fraction, PMNL were sonicated (3 cycles of 
30 sec, sub-maximal potency), and centrifuged at 
2000 x g for 10 min at 0º C. The supernatant was 
centrifuged at 100 000 x g for 1 hour at 4º C, and 
then the fraction was frozen at -20º C until the 
activity test (Boyum, 1983). 
 
Effects of D-005 on COX enzyme activity 
COX activity was measure accordance to Abad et al., 
(1994). The reaction mixture contained 2 mmol/l AA; 
microsomal fraction (1 mg/ml); 5.8 mmol/l L-
epinephrine and 0.05 mol/l Tris HCl buffer (pH = 
8.4). Tubes containing the vehicle, D-005 (0.9, 3.9, 
15.6, 62.5, 250, 500, or 1000 g/ml), or INDO (0.4 
g/ml) (reference inhibitor of COX) and D-004 500 
g/ml (dual inhibitor of COX and 5-LOX) were run. 
Then, mixture reactions were preincubated with L-
epinephrine for 4 min and then AA at 37º C was 
added. The changes of absorbance at 480 nm were 
measured for 10 min in the spectrophotometer. The 
enzyme activity was expressed in OD 480 nm 
changes/mg of protein. 
Each experiment was run in triplicate and the 
results averaged. The concentration producing a 50% 
inhibition (IC50) was calculated from the outline of 
the inhibition percentages as a function of the 
concentrations of D-005. The effects on COX 
reaction rates were assessed as the increase in the 
substrate (AA) concentrations (7.8, 31.2, 62.5, 125, 
250 mmol/l). 
Once the substrate was added, increase in 
absorbance was measure at 234 nm every min for 10 
min. The enzyme activity was expressed as mol of 
conjugated dienes/min/mg protein. The initial 
reaction rate was determined from the slope of the 
straight line portion of the curve and the percentage 
inhibition of the enzyme activity was calculated by 
comparing with the control samples. 
 
Effects of D-005 on 5-LOX enzyme activity 
Lipoxygenase is known to catalyse the oxidation of 
unsaturated fatty acids containing 1-4 diene 
structures. The conversion of linoleic acid to 13- 
hydroperoxy linoleic acid was followed 
spectrophotometrically by the appearance of a 
conjugate diene at 234 nm. In brief, the enzyme 
preparation (1 ml, final volume) that contained the 
cytosolic fraction (50µg of protein) dissolved in 50 
mmol/l phosphate buffer/1mmol/l EDTA (pH = 7) 
was pre-incubated for 5 min prior to the addition of 
the substrate (linoleic acid 250 µmol/l in ethanol). 
Tubes containing the vehicle, D-005 (0.9, 3.9, 15.6, 
62.5, 250, 500, or 1000 g/ml), INDO 0.4 g/ml 
(COX, not LOX inhibitor), or D-004 500 g/ml (dual 
inhibitor of COX and 5-LOX) were run. Once the 
substrate was added, the increase of absorbance at 
234 nm was measured every min for 10 min in the 
spectrophotometer. The enzyme activity was 
expressed as moL of conjugated dienes/min/mg 
protein. The initial reaction rate was determined from 
the slope of the straight line portion of the curve and 
the percentage inhibition of the enzyme activity was 
calculated by comparing with the control samples 
(Tateson et al., 1988). 
Each experiment was tested in triplicate and 
the results averaged; the concentration that gave 50% 
inhibition (IC50) was calculated from the outline of 
the inhibition percentages as a function of the 
inhibitor concentration. The effects of D-005 on the 
initial rate of 5-LOX reaction (Vmax) were assessed 
as the increase in the substrate concentration (linoleic 
acid 7.8, 31.2, 62.5, 125, and 250 mmol/l). 
 
Statistical analyses 
All the analyses were carried out in triplicate and the 
data were expressed as the mean ± standard 
deviation. Comparisons between treated and control 
groups were performed with the Mann-Whitney U 
and the ANOVA tests. Statistical significance was 
chosen for α = 0.05. Dose-effect relationships were 
assessed by using a linear regression and correlation 
test. Regression analysis was used to calculate IC50, 
defined as the concentration of inhibitor necessary for 
50% inhibition of the enzyme reaction. Data were 
processed with the Statistics Software for Windows 
(Release 4.2 Stat Soft Inc, Tulsa OK, US). 
 
Perez et al. Inhibition of COX and 5- LOX by D-005 
 
 
 Boletín Latinoamericano y del Caribe de Plantas Medicinales y Aromáticas/323 
RESULTS 
Effects of D-005 on COX-1 and COX-2 activities 
Table 1 lists the effects on COX-1 activity. The 
addition of D-005 (0.9-1000 g/ml) did not modify 
significantly the enzyme activity, although an 
 
apparent reduction of almost 30% as compared to the 
control was noted. INDO 0.4 g/ ml, not D-004 500 
g/ ml, produced a significant (P< 0.01) and marked 
inhibition of COX-1 activity (94.8%). 
 
Table 1 
Effects of D-005 on COX-1 enzyme activity in rat platelets microsomes 
Groups Concentrations 
(μg/ml) 
Enzyme activity 
(OD/min/mg protein) 
Inhibition 
(%) 
Control 0 0.350 ± 0.01 - 
D-005 0.9 0.342 ± 0.04   2.2 
D-005 3.9 0.282 ± 0.01 19.4 
D-005 15.6 0.270 ± 0.08 22.8 
D-005 62.5 0.245 ± 0.06 30.0 
D-005 125 0.243 ± 0.05 30.5 
D-005 250 0.243 ± 0.05 30.5 
D-005 500 0.242 ± 0.06 30.8 
D-005 1000 0.242 ± 0.06 30.8 
D-004 500 0.316 ± 0.01   9.7 
Indomethacin 0.4     0.018 ± 0.01** 94.8 
(Mean ± SD) **P < 0.01 Comparison with the control (Mann Whitney U test) 
 
All added substances inhibited significantly COX-2 
activity (Table 2). D-005 (0.9-1000 g/ml) produced 
a significant, dose-dependent (r = 0.968; P < 0.001) 
and marked (95.1%) inhibition of COX-2 activity 
(IC50 = 6.17g/ml). In addition, INDO 0.4 g/ml and 
D-004 500 g/ml inhibited significantly (P < 0.01 
and P < 0.05, respectively) COX-2 by 97.1% and 
85.0%, respectively.  
Table 2 
Effects on COX-2 activity in rat seminal vesicle microsomes 
Groups Concentrations  
(μg/ml) 
Enzyme activity 
(OD/min/mg protein)   
Inhibition (%) 
Control 0 0.351 ± 0.01 - 
D-005 0.9 0.288 ± 0.23 17.9 
D-005 3.9 0.191 ± 0.15* 45.5 
D-005 15.6 0.147 ± 0.05* 58.1 
D-005 62.5 0.063 ± 0.01* 82.0 
D-005 125 0.044 ± 0.01* 87.4 
D-005 250 0.035 ± 0.01** 90.0 
D-005 500 0.019 ± 0.01** 94.5 
D-005 1000 0.017 ± 0.01** 95.1 
D-004 500 0.053 ± 0.02* 85.0 
Indomethacin 0.4 0.010 ± 0.01** 97.1 
(Mean ± SD) *P < 0.05, **P < 0.01 Comparison with the control (Mann Whitney U test) 
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The inhibition of COX-2 activity by D-005 involved 
the modification of both kinetic parameters (Vmax 
and Km) (Figure 1, Lineweaver-Burk plots), so that 
the inhibition was uncompetitive. 
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Figure 1 
Lineweaver-Burk plot (1/v0 versus1/[S]0) of the effect of D-005 (62.5 µg/ml) on the initial rate of the enzyme 
reaction measured in front of increasing concentrations of the substrate (arachidonic acid 7.8, 31.2, 62.5, 125 
and 250 mmol/l). D-005 modified the values of both kinetic parameters Km (-1/Km, intercept with abscise 
axis) and Vmax (1/Vmax, intercept with the ordinate axis) of COX-2 enzyme activity. 
 
Effects of D-005 on 5 LOX activity 
Table 3 summarizes the effects on 5-LOX activity. 
D-005 (0.9-1000 g/ml) addition to PMNL 
preparations significantly, dose-dependently (r = 
0.909; P < 0.002) and markedly inhibited 5-LOX 
activity (94.5%) (IC50 = 140.7 g/ ml). D-004 500 
g/ml inhibited significantly (P < 0.01) 5-LOX 
activity by 91.4 %, while INDO was ineffective 
modifying the enzyme activity.  
 
Table 3 
Effects of D-005 on 5-LOX activity in cytosolic fraction of polymorphonuclear leukocytes (PMNL) 
Groups Concentrations 
(μg/ml) 
Enzyme activity 
(OD/min/mg protein)   
Inhibition 
 (%) 
Control 0 11.00 ± 0.01 - 
D-005 0.9 10.70 ± 2.50 2.7 
D-005 3.9 9.70 ± 1.10 11.8 
D-005 15.6 9.40 ± 1.80 14.5 
D-005 62.5 8.80 ± 1.90 20.0 
D-005 125 6.30 ± 1.40* 45.7 
D-005 250 1.85 ± 1.25 ** 83.1 
D-005 500 0.95 ± 0.35 ** 91.3 
D-005 1000 0.60 ± 0.01 ** 94.5 
D-004 500 0.95 ± 0.35 ** 91.4 
Indomethacin 0.4 11.1 ± 2.20 0 
(Mean ± SD) *P<0.05, **P<0.01 Comparison with the control (Mann Whitney U test) 
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The addition of D-005 modified both kinetic 
parameters (Vmax and Km) of COX and 5-LOX 
enzyme activities (Figure 2, Lineweaver-Burk plots), 
so that 5-LOX inhibition by D-005 was 
uncompetitive. 
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Figure 2 
Lineweaver-Burk plot (1/v0 versus1/[S]0) of the effect of D-005 (62.5 µg/ml) on the initial rate of the enzyme 
reaction measured in front of increasing concentrations of the substrate (linoleic acid 7.8, 31.2, 62.5, 125 and 
250 mmol/l). D-005 modified the values of both kinetic parameters Km (-1/Km, intercept with abscise axis) 
and Vmax (1/Vmax, intercept with the ordinate axis) of 5-LOX enzyme activity. 
 
DISCUSSION 
In this study we demonstrated that the addition of D-
005 (0.9 - 1000 g/ml) inhibited significantly, dose-
dependently and markedly (about 95% in both cases) 
COX-2 activity in the microsomal fraction of rat 
seminal vesicles, and 5-LOX activity in the cytosolic 
fraction of rat PMNL in vitro, without modifying the 
activity of COX-1 in rat platelets microsomal 
fraction. 
Despite the observation that D-005 produced 
an apparent decrease of COX-1 activity versus the 
control, such reduction was not significant, its 
magnitude was modest to moderate (about 30%) and 
constant across a wide concentration range (62.5 to 
1000 g/ml) we acknowledge that D-005 failed to 
inhibit COX-1 in this study. 
INDO inhibited significantly and markedly 
COX-1 (94.8%) and COX-2 activities (97.1%) 
leaving unaffected 5-LOX activity, as expected of a 
non-selective COX inhibitor (Martel-Pelletier et al., 
2003); while D-004 inhibited significantly COX-2 
(85%) and 5-LOX (91.4%), consistently with 
previous reports (Menéndez et al., 2006; Menéndez 
et al., 2007). These facts validate the assessment of 
enzyme activities under our experimental conditions 
and the results.  
The addition of D-005 inhibited markedly 
COX-2 and 5-LOX (maximal inhibitions of about 
95% in both cases) rat seminal vesicles preparations 
and rat PMNL, respectively. Nevertheless, D-005 
appears to be more potent to more potent inhibitor of 
COX-2 (IC50 = 36.08 g/ml) than 5-LOX (IC50 = 
140.7g/ml), which suggests that D-005 has a higher 
affinity for COX-2 than for 5-LOX enzyme. 
The nature of the inhibitions of COX-2 and 
5-LOX by D-005 was uncompetitive, since in both 
cases D-005 addition modified the two kinetic 
parameters (Vmax and Km) of COX-2 activity. 
These results suggest that D-005 does not interact 
directly with the active site of these enzymes to 
curtail the enzyme reaction, but with a site near to it. 
This interaction, however, should be strong since 
inhibitions of COX-2 and 5-LOX achieved with D-
005 were not just significantly, but actually 
meaningful (≥ 90% in both cases). In the case of 
COX-2 this statement is reinforced by the fact that 
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INDO, an effective unspecific COX inhibitor, 
produced a COX-2 inhibition of about 97.0%, near to 
that caused by D-005. In turn, at similar 
concentrations (500 g/ml) the inhibition of COX-2 
by D-005 was slightly superior (about 95%) than that 
reached with D-004 (about 85%), Nevertheless in the 
present study, we cannot reach to conclusions about 
the potency and efficacy of both substances (D-005 
and D-004) on this model because we did not 
compare concentration versus effects relationships of 
both treatments, but only tested the effect of one 
concentration of D-004.  
  According to the present results, D-005 acts 
as a dual COX/5-LOX inhibitor. It is known that dual 
acting anti-inflammatory drugs, able to inhibit COX 
and 5-LOX, seem to retain the activity of non-
steroidal anti-inflammatory drugs (NSAIDs) while 
avoiding their main adverse effects. NSAIDs display 
their anti-inflammatory action mainly through 
inhibition of COX, thus interfering with the 
production of gastroprotective prostaglandins and 
then, displacing the AA metabolism towards the 
increase of the production of pro-inflammatory, 
bronchoconstrictive and gastrotoxic leukotrienes 
(LTs). Although D-005 inhibits markedly COX-2, its 
inhibitory action on 5-LOX should prevent the switch 
to the increased production of LTs (Leone et al., 
2007; Van Wauwe & Goossens, 2009). Previous 
studies had demonstrated that saturated and 
unsaturated fatty acids, such as myristic, steraic, 
palmitic, oleic and several oils extracts containing 
fatty acids inhibit COX and LOX, in vitro (Naidu, 
1995; Chan et al., 1996; Henry et al., 2002; Zhang et 
al., 2002; Menéndez et al., 2007). These fatty acids 
had demonstrated anti-inflammatory effect in vivo 
and clinical assay (Menéndez et al., 2006; Zhang et 
al., 2008; Ravelo et al., 2011).  
The present results add knowledge on the 
pharmacological effects of lipid extracts obtained 
from palm fruits, in particular obtained from 
Acrocomia crispa, specie endemic to Cuba which 
hasn’t been studied enough as researched subject. 
The present results encourage the investigation of the 
effects of D-005 on experimental models of acute and 
chronic inflammation in vivo.  
 
CONCLUSIONS 
This study demonstrates that D-005, a lipid extract 
obtained from Acrocomia crispa fruits, inhibited 
COX-2 and 5-LOX enzyme activities, with highest 
affinity for COX-2. The dual inhibition of COX-2 
and 5-LOX suggests that D-005 could produce anti-
inflammatory effects. 
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